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Abstract
Background: Disease incidence and prevalence are both core indicators of population health. Incidence is
generally not as readily accessible as prevalence. Cohort studies and electronic health record systems are two
major way to estimate disease incidence. The former is time-consuming and expensive; the latter is not available
in most developing countries. Alternatively, mathematical models could be used to estimate disease incidence
from prevalence.
Methods: We proposed and validated a method to estimate the age-standardized incidence of cardiovascular
disease (CVD), with prevalence data from successive surveys and mortality data from empirical studies. Hallett’s
method designed for estimating HIV infections in Africa was modified to estimate the incidence of myocardial
infarction (MI) in the U.S. population and incidence of heart disease in the Canadian population.
Results: Model-derived estimates were in close agreement with observed incidence from cohort studies and
population surveillance systems. This method correctly captured the trend in incidence given sufficient waves
of cross-sectional surveys. The estimated MI declining rate in the U.S. population was in accordance with the
literature. This method was superior to closed cohort, in terms of the estimating trend of population cardiovascular
disease incidence.
Conclusion: It is possible to estimate CVD incidence accurately at the population level from cross-sectional
prevalence data. This method has the potential to be used for age- and sex- specific incidence estimates, or
to be expanded to other chronic conditions.
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Background
Disease incidence and prevalence are core indicators of
population health. Accurate estimates of chronic diseases
prevalence and incidence are essential for assessing popu-
lation burden of disease and determining health priorities
[1]. Incidence (rate of new cases among those at risk) is a
better indicator of the progress of a disease epidemic, in
comparison to prevalence (fraction of the population with
the condition) for several reasons. First, change in preva-
lence lags behind the actual changes in population risk
and incidence. Second, prevalence reflects historical trend
and accumulation of cases, rather than recent incidence
change. Many factors other than recent incidence change,
such as population aging and survival improvement may
influence the change in prevalence [2]. This is especially
relevant to conditions such as myocardial infarction (MI)
or stroke, a considerable portion of which are silent or
transitory [3, 4]. Some affected individuals may not seek
medical care, although they are at similar risk for adverse
outcomes such as mortality when compared to individuals
with detectable signs and symptoms. Many of the first
occurrences of MI and stroke are fatal [5], such that
recorded incidence of such conditions typically based on
hospitalized cases is likely to underestimate the actual
disease burden.* Correspondence: laurie.chan@uottawa.ca1Department of Biology, University of Ottawa, 180B, Gendron Hall, 30 Marie
Curie, Ottawa, ON K1N 6 N5, Canada
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Hu et al. BMC Medical Research Methodology  (2017) 17:9 
DOI 10.1186/s12874-016-0288-y
The most direct approach to estimating cardiovascular
disease incidence is through longitudinal observational
studies. Such studies are time-consuming, expensive, and
are disease specific. Electronic health record systems and
disease registry systems provide new sources of incidence
estimates, but these are not available in most of the devel-
oping countries. Alternatively, incidence could be esti-
mated by mathematical models, with prevalence data at
multiple time points, population demographic change,
and mortality as fundamental input. Prevalence of cardio-
vascular disease, typically from cross-sectional surveys, are
generally more easily obtainable [6]. Mathematical models
with varying degrees of sophistication have been devel-
oped, including Hallett’s method to estimate HIV inci-
dence in Africa [7–9]. Theoretically, Hallett’s framework
should be applicable in different settings and for other
diseases as long as the disease is not reversible and local
population/mortality data are available [6, 9]. However,
the assumptions in this model were based on the HIV
epidemic in Africa, and may not be applicable for cardio-
vascular diseases in a developed country.
Developing and testing a prevalence-incidence model
(PI model) for cardiovascular diseases has both global
and local significance. In Canada, for example, it is no
longer possible to estimate the incidence of self-reported
cardiovascular disease after the closing of the National
Population Health Survey (NPHS) in 2012 [10]. While
electronic health record systems are being set up in
many locations across Canada, there is as yet no linked,
national database. Reporting of all heart attack episodes
(including silent cases and fatal cases) were rare, al-
though hospitalized heart attack incidence rate was more
frequently reported [11]. The PI model would be espe-
cially relevant for remote areas, in which cohort studies
or electronic health record systems are likely to be un-
available. A PI model would also help to identify the gap
between reported and true cardiovascular disease inci-
dence, indicating priorities for health services planning.
In this study, we propose to modify the Hallett’s
method and test its applicability to estimating cardiovas-
cular disease incidence in the North America setting.
We shall determine the hazard/probability of developing
new cases across the time interval between two cross-
sectional surveys and generate age-standardized incidence
rates. We shall compare model estimated incidence rates
with those obtained from cohort studies and population
monitoring programs. If sufficient waves of cross-sectional
surveys are available, the model could potentially also de-
tect trends.
Methods
The HIV prevalence-incidence model
Among PI models with different complexities, the one
proposed by Hallett et al. has been widely cited and used
[9]. Detail of model derivation and validation has been
published elsewhere [9]. Briefly, the difference between
observed prevalence in the second survey and the ex-
pected prevalence (estimated from prevalence in the first
survey and survival fraction based on mortality) provides
the incident cases; the proportion of disease-negative
people, the mortality rate for these people and the time
interval between the two cross-sectional surveys to-
gether generate the number of person-years. Age- and
gender- specific prevalence and mortality should be used
to obtain more accurate estimates. Mortality of people
with/without the health outcome of interest can be
based on population vital statistics or the literature. The
model assumes prevalence and mortality are constant
during the interval of two successive surveys to keep the
model simple and easy to use.
Model adjustment and validation for cardiovascular
diseases
Hallett’s method should work for other diseases and set-
tings as long as the disease is not reversible. We made two
major modifications to Hallett’s method to better fit car-
diovascular diseases. First, the survival fraction of disease
positive patients is estimated as a function of 30-day case
fatality, 1-year, 5-year and 10-year survival/mortality rate
whenever possible, instead of assuming a constant mortal-
ity rate between the time intervals of two surveys. Second,
we calculated the age-standardized incidence rate to make
the estimate more comparable to other health statistics in
its target population.
Model validation
We tested the performance of our modified Hallett’s
method in two steps. First, we applied our model to esti-
mate myocardial infarction (MI) incidence in the US
population and compared estimated values to reported
incidence rates from the national environmental public
health tracking network (Tracking Network) of U.S.
Centers for Disease Control and Prevention (CDC),
existing epidemiological studies and population statistics.
We chose MI in the US population as this condition was
one of the most well studied cardiovascular outcomes.
The mortality, prevalence, and survival data were rela-
tively accurate and robust. Second, we expanded the out-
come to the broader category of any heart disease (HD),
which also includes heart failure and other forms of
heart diseases, and compared incidence estimates with
observed incidences from a national representative co-
hort study, in Canada. The cross-sectional surveys and
the longitudinal survey we used share the same sampling
framework and chronic disease module in their ques-
tionnaires. In the text hereafter, heart disease refers to
combined MI, angina and heart failure in the Canadian
population without further specification.
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Data source
For the United States, we chose the National Health and
Nutrition Examination Survey (NHANES), which pro-
vides MI prevalence estimates in the US population at
two-year intervals from 1999 to 2012 [12]. NHANES is a
repeated cross-sectional survey of a nationally represen-
tative sample of the US population, with a multistage,
stratified sampling design. Our study population in-
cluded all participants aged 35 years and older in the 7
consecutive waves of the survey. Participants who an-
swered “Yes” to questionnaire item MCQ160e (“Has a
doctor or other health professional ever told you that
you had heart attack (also called myocardial infarction)”)
will be classified as prevalent MI cases in this study.
Sex-specific mortality data for MI patients were calcu-
lated from hospitalized mortality and 2-year mortality
after hospital discharge [13, 14]. Mortality data for the
MI-negative population were calculated as the difference
between all-cause mortality rate and the mortality rate
of MI, from “Underlying Cause of Death 1999-2011” on
the CDC WONDER Online Database [15]. Hospitalized
MI incidence data were based on 26 States which partic-
ipated in the CDC environmental public health tracking
program [16].
For Canada, we selected the Canadian Community
Health Survey (CCHS), which provides prevalence of
self-reported heart diseases in the Canadian population,
also at two-year intervals from 2001 to 2011 [17]. The
CCHS is a series of cross-sectional surveys conducted
biannually before 2007 and yearly since then. It uses a
stratified, multistage probability sampling design. It col-
lects information on health status, health care utilization
and health determinants for the Canadian population. In
this study, we identified participants aged 12 years and
older in 6 consecutive waves of the survey. Participants
who answered “Yes” to questionnaire item CCQ121
(“Have you had heart diseases which lasted 6 months or
more and have been diagnosed by a health profes-
sional?”) were classified as prevalent heart disease cases.
The mortality rate of heart disease was calculated as the
total of mortality from MI, angina and heart failure.
Mortality rates for MI patients were assumed to be the
same as the US population because studies suggest that
2-year mortality rates after MI are comparable between
the two populations [13, 14, 18]. Mortality rates for an-
gina and heart failure patients were based on Ontario
data [19]. Mortality rates for heart disease free patients
were calculated as the difference between all-cause mor-
tality and mortality from heart disease, basing on data
from Statistics Canada’s Canadian Mortality Database, as
available online from the CANSIM Table “Cause of
Death 2000-2011” [20]. Heart disease incidence rates
were calculated from the NPHS, which is a longitudinal
health survey [21]. It started in 1994/1995 with an initial
sample size of 17276 and ended in 2012 after another 8
follow-ups, which was conducted every two years.
Statistical analysis
The incidence rate of the outcome of interest in each
age- and sex- group is estimated by equation (1), where
Ii is the incidence, Fi approximates the proportional
cohort size change over the time interval between two
surveys (which was given by equation (2)), SPi is the
proportion of disease-positive patients at the beginning
of the first survey who survive to the next survey, SNi is
the corresponding proportion for the disease-negative
people, pi,0 is the prevalence of outcome of interest at
the first survey, pi,T is the prevalence at the second sur-
vey respectively. In this paper, the time intervals for both
the NHANES and the CCHS were 2 years. Equation (1)
calculates the point estimates of incidence. Poisson-
based confidence intervals for incidence can be esti-
mated, treating the survey as a simple random design,
without considering the survey design and sampling pro-
cedure. After obtaining the crude incidence rate for each
age- and sex- group, a standardized incidence for the
population is calculated using the direct method. For the
United States cohort, we used the total US population in
2000 as the standard population; for the Canadian
cohort, we used the total Canadian population from the
2001 Census. As each wave of the NHANES and the
CCHS covers two years (e.g. 1999–2000, 2001–2002),
the incidence estimated from such two waves was pre-
sented as between January 1st of the second year of each
wave, i.e.,between Jan 1, 2000, and Jan 1, 2002.
Sex-specific five-year age group was used as the smal-
lest analytic unit. Prevalence estimates for each age- and
sex- group were calculated with proper sample weights
and survey design effect used by the NHANES and the
CCHS. It was substituted with the value from next age
group if the prevalence was zero in the very young age
groups. Baseline 2-year mortality after MI was calculated
with equation (3), for both the US population and the
Canadian population, where MMIin denotes MI mortality
in hospital, and MMIout denotes MI mortality after
hospital discharge. A 3% decrease in mortality rate for
MI positive patients each year was assigned according to
the literature [22]. The 2-year survival fraction for MI
patients (SPMI) was given by equation (4). Baseline 2-
year survival fraction after heart disease (SPHD) for the
Canadian population was calculated with equation (5),
where wMI,wAG,wHF denotes the weighted proportion of
MI/angina/heart failure to the sum of the three (in the
CCHS cycle 2001). The mortality rate for MI or heart
disease negative people were calculated with equation
(6) and (7), as the difference between all-cause mortality
(MVAll − cause) and MI/heart disease mortality (MVMI,
MVHD) from population vital statistics. The observed
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incidences of hospitalized MI in the US population were
retrieved from CDC report, epidemiological studies and
population statistics [2, 16, 23]. The observed incidences
of heart disease in the Canadian population were calcu-
lated with corresponding weights from NPHS. In this
paper, we will use the term “estimated” to refer to model
calculated incidence, and the term “observed” to refer to
incidence estimated from a cohort study, or reported in




T 1−pi;0 þ Fi 1−pi;T
   ð1Þ
Fi≈1− 1−SPið Þpi;0− 1−SNið Þ 1−pi;0
 
ð2Þ
MMI ¼ MMIin þ 1−MMIinð Þ MMIout ð3Þ
SPMI ¼ 1−MMI ð4Þ
SPHD ¼ 1−MMI WMI−MAG WAG−MHF WHF ð5Þ
SNMI ¼ 1− MVAll−cause−MVMIð Þ ð6Þ
SNHD ¼ 1− MVAll−cause−MVHDð Þ ð7Þ
To validate the model performance, we compared the
estimated incidence with observed values. We checked
whether our estimated incidence fall into the high-low
range (or 95% CIs) of observed incidence. When the def-
inition of best available reported outcome is different
from what we modeled, we adjusted our estimated
values to make a fair comparison. For example, the most
reliable statistics in the US population was hospitalized
MI incidence. Thus we adjusted downward our estimated
values, considering about 30% of MI would be silent cases,
and another 20% would be fatal cases, to be more compar-
able [4, 24, 25]. The time trend of estimated incidence was
investigated by fitting a linear regression, with estimated
incidence as the y outcome and survey year minus 2000
as the single x predictor.
Results
US Data
Estimated MI incidence in the US population (aged
35 years and older) from 2000 are provided in Table 1.
The estimated MI incidence was 843 (1/100,000)
between 2000 and 2001, and 678 (1/100,000) from 2010
to 2011, with a decreasing trend. The highest estimated
MI incidence from the model was observed in 2002–
2003. We also estimated hospitalized MI incidence to be
56% of MI incidence. Linear regression showed that the
MI incidence decreased by approximately 32 (1/100,000)
each year since 2000. The corresponding decrease in
hospitalized MI was approximately 18 (1/100,000) re-
spectively, which translated to a 3.8% decrease annually.
We projected a 38% reduction in hospitalized MI inci-
dence from 2000 to 2010, based on the prevalence from
NHANES. Our hospitalized MI incidence estimates were
compared against the reported values from those States
which participated in the CDC environmental public
health tracking program from 2000 to 2011 (Fig. 1). All
of our estimated incidences fell into the high-low range
of the reported values.
Canadian data
The model estimated heart disease incidence from
CCHS, and observed heart disease incidence (with 95%
CIs) from NPHS, for the Canadian population aged
12 years and older are shown in Table 2. We modelled
two sets of heart disease incidence, with one set stan-
dardized to the NPHS age structure, and another set
standardized to 2001 Canadian Census population. Our
estimated heart disease incidence (first set) were very
close to the NPHS values, with the smallest relative dif-
ference observed in 2009–2011 (0.7%), and the largest
observed in 2003–2005 (12.9%). All of our first set esti-
mated heart disease incidence fell into the 95% CIs of
NPHS heart disease incidence. Figure 2 visually depicts
how close between the NPHS incidence and our esti-
mated incidence. The second set of heart disease inci-
dence showed a decreasing trend among the Canadian
population from 2001 to 2011. On average, heart disease
incidence decreased by 13 (1/100,000) each year from
2001. The difference between the two sets of estimated
heart disease incidence was due to the different age
structures of the NPHS and the 2000 Canadian Census
we used during direct standardization.
We provide the model input, which is also part of the
results, in the Appendix. The mortality rate of acute MI
during hospitalization, the 2-year mortality rate of acute
MI after hospital discharge, and the survival fraction
2 years after acute MI for the U.S. population in 1999 are
presented in Table 3 in Appendix. The prevalence of MI
Table 1 Estimated incidence rate of all and hospitalized myocardial infarction in the US population from 2000 to 2011 (1/100000)
2000–2001 2002–2003 2004–2005 2006–2007 2008–2009 2010–2011
Estimated incidence of all MI 843 998 546 498 543 678
Estimated incidence of hospitalized MIa 472 559 306 279 304 380
a56% of all the myocardial infarctions will be hospitalized basing on the assumption that 30% of the myocardial infarction events are fatal, and 20% of the
myocardial infarction are silent (thus not hospitalized).
Incidence of myocardial infarction = 843-32*(year-2000); Incidence of hospitalized myocardial infarction = 540-18*(year-2000)
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in the U.S. population from 1999 to 2009 (in a 2-year
time interval) estimated from NHANES are shown in
Table 4 in Appendix. Table 5 in Appendix shows the
2-year mortality rate after MI, angina, heart failure,
and the constructed 2-year survival fraction after
heart disease. Table 6 in Appendix presents the
prevalence of heart disease in the Canadian popula-
tion, calculated from CCHS 2001 to 2011. Hospital-
ized MI incidence data from 26 States which
participated in the CDC environmental public health
tracking program (from 2000 to 2012) are provided in
Table 7 in Appendix. Table 8 and 9 in Appendix provide
the population age structure of the U.S. population and
the Canadian population used for standardization,
respectively.
Discussion
A useful prevalence-to-incidence method was tested
and validated for cardiovascular diseases in the
general population of USA and Canada in this paper.
Accurate estimates of cardiovascular disease incidence
are still not available for populations not served by
electronic health care information systems, or repre-
sentative longitudinal surveys. Such data are lacking
for sub- populations undergoing rapid health transi-
tion, with a rapidly increasing burden of cardiovascu-
lar diseases, such as indigenous people in North
America. The prevalence-to-incidence method offers
an alternative option to monitor, and compare the
emerging cardiovascular disease pandemic, both glo-
bally and locally. Although we tested the method
using cardiovascular health outcomes, it should also
apply in other chronic conditions as long as the con-
dition is irreversible
Estimates of hospitalized MI incidence in the U.S.
population were in very close agreement with the actual
statistics [16, 23]. Our MI incidence estimates can the-
oretically capture all MI cases. Hospitalized MI inci-
dence miss those individuals who do not receive
medical care, or died before reaching care. To better
compare and validate our method, we made assump-
tions to convert all MI incidence to hospitalized MI
incidence based on literature [4, 24, 25]. All of our
estimated incidences fell into the high-low range of
reported hospitalized MI incidence in the correspond-
ing year. Estimates of hospitalized MI incidence were
close to the low end of reported values in certain years.
Several reasons might explain that. First, the NHANES
was designed to represent the U.S. population demo-
graphically, its prevalence estimates for a certain dis-
ease varied across waves to some extent. For example,
the prevalence of MI in female in the 2009 wave was
substantially lower, while the prevalence in male in the
2003 wave was substantially higher than neighboring
waves. The fluctuation in prevalence would lead to vari-
ation in incidence estimates. Second, the definitions of
MI in the NHANES and Tracking Network of CDC
might not match exactly. What NHANES recorded was
the self-reported doctor confirmed MI. The self-
reported data generally suffered from recall bias,
Fig. 1 Observed and modelled hospitalized myocardial infarction
incidence rate in the US from 2000 to 2011. The high/low boundary of
the grey area represents the highest/lowest hospitalized myocardial
infarction rate at state level recorded in the national environmental
public health tracking network of U.S. Centers for Disease Control and
Prevention. The diamond points represent the estimated national
hospitalized myocardial infarction rate by our model
Table 2 Incidence rate of heart diseases in NPHS cohort and model estimates for the Canadian population from 2001 to 2011 (1/
100000)
2001–2003 2003–2005 2005–2007 2007–2009 2009–2011
NPHS incidence 983 1025 1003 1031 1016
lower 95% CI of reported incidence 831 845 840 852 802
upper95% CI of reported incidence 1136 1204 1165 1209 1230
Estimated incidence 1a 1018 893 918 1097 1023
Estimated incidence 2b 927 779 783 873 752
aEstimated incidence 1, standardized to NPHS age structure
bEstimated incidence 2, standardized to 2000 Canadian census population
Incidence of heart disease (standardized to 2000 Canadian census population) = 887-13*(year-2000)
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compared to the hospital discharge data used by the
CDC Tracking Network. Third, this study used data
covering more than 10 years. Changes in diagnostic
techniques and criteria, in the coding of MI, or in
medical care access may all contribute to the fluctu-
ation of MI incidence, both estimated from the model
and reported by the CDC Tracking Network [26]. In
addition, we used the same ratio to adjust overall MI
incidence to hospitalized MI incidence for all the years,
and that might also introduce some uncertainties.
A declining trend was observed from our hospital-
ized MI incidence estimates, as well as the reported
values from the Tracking Network of CDC. Another
study showed a very similar trend of acute MI
incidence rate from 1999 and 2008 in Northern
California, the incidence of which also peaked around
the year 2001 and then decreased gradually [11]. Our
method yielded an average annually 3.8% decrease of
hospitalized MI incidence in the general U.S. popula-
tion, comparing to a 2.4% decrease in acute MI in
North California from 1999 to 2008 [11], a 5.8%
decrease in acute MI among the Medicare fee-for-
service beneficiaries from 2002 to 2007 [27], and a
4.9% decrease in age- and biomarker-adjusted inci-
dence of hospitalization for AMI or fatal CHD in the
Atherosclerosis Risk in Communities Study (ARIC)
from 1987 to 2008 [28]. As summarized above, the
decreasing rate identified from our estimates was also
in accordance with reported values from cohort stud-
ies or surveillance data.
We further tested our method in the Canadian popula-
tion. The NPHS and the CCHS share similar survey
framework and the same questionnaire for chronic
conditions [17, 21]. Our heart disease incidence esti-
mates from different cycles of the CCHS were very
close to the NPHS heart disease incidence when we
standardized to the NPHS age structure. That result
demonstrated that our method could provide accurate
incidence estimate as a cohort study. More interest-
ingly, the heart disease incidence estimates decreased
constantly since 2001 if we standardized the results
to the Canadian census population. This fact showed
that our method was actually superior to closed co-
hort study (without buy-in participants during follow-
up), in terms of estimating the incidence and its
trend over time. It would be more consistent if we
validated our method using MI as the outcome in the
Canadian population first, however, unfortunately, the
CCHS stopped to ask about MI since 2004. We derived
the mortality of heart disease based on information for
MI, angina and heart failure. The good agreement
between incidence estimates and cohort study values
demonstrated that other than a single health outcome
(e.g. MI), this method could also be used for health
outcomes with multiple components, e.g. heart disease
(MI, angina, and heart failure), potentially stroke
(ischemic, hemorrhagic, and unspecified) and other
health outcomes.
Our modelling method also has limitations. It
depends on the quality of prevalence and mortality
data, and the extent of such data available. Assump-
tions and robust sensitivity analyses become essential
in some circumstances. Our method was tested in
short survey interval and small age- and sex- group
basis. The combined incidences for male and female,
and for all ages were compared against cohort study
or population statistics. Future work is planned to
test the model performance for subgroups, e.g. male
and female separately, or in certain specific age
group. The application of this method in other
chronic conditions also needs to be tested, especially
when their prevalence and mortality differ from MI
or heart disease substantially.
Conclusion
In conclusion, a reliable prevalence to incidence
method for cardiovascular health outcomes was tested
and validated. The incidence estimates given by the
method were on average within 10% of the values
from a cohort study. This method could also capture
the trend of incidence if multiple cross-sectional data
are available. This method has the potential to be
used in population without valid cardiovascular dis-
ease incidence statistics.
Fig. 2 Observed and modelled incidence of heart disease in the
Canadian population from 2001 to 2011. The dark grey bars with
confidence intervals represent the estimated incidence of heart
disease from the National Population Health Survey. The light
grey bars represent the estimated incidence of heart disease
from our model. All the predicted values were within the 95%
CIs of the observed incidence. The average difference between
the predicted values and the observed incidence were less
than 10%
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Appendix
This files includes 7 tables with the following data: 1)
Cohort mortality for US population with and without
acute myocardial infarction in 1999, 2) Prevalence of myo-
cardial infarction in NHANES participants (%), 3) Cohort
mortality for Canadian population with and without heart
disease in 2001, 4) Prevalence of heart disease in CCHS
participants (%), 5) Hospitalized MI incidence in different
states in the U.S. from 2000 to 2012, 6) Age distribution
by sex, 2000 US population (%), 7) Age distribution by
sex, 2001 Canadian population (%).
Table 3 Cohort mortality for US population with and without acute myocardial infarction in 1999a







mortality rate after AMIb
(c)
Survival fraction






35–49 0.029 0.060 0.087 0.913 0.003
50–54 0.041 0.083 0.121 0.879 0.006
55–59 0.057 0.083 0.135 0.865 0.009
60–64 0.082 0.172 0.240 0.760 0.014
65–69 0.107 0.172 0.261 0.739 0.022
70–74 0.144 0.289 0.391 0.609 0.034
75–79 0.184 0.289 0.420 0.580 0.052
80+ 0.218 0.513 0.619 0.381 0.083
Women
35–49 0.061 0.120 0.174 0.826 0.002
50–54 0.074 0.115 0.180 0.820 0.004
55–59 0.095 0.115 0.199 0.801 0.006
60–64 0.111 0.184 0.275 0.725 0.009
65–69 0.134 0.184 0.293 0.707 0.014
70–74 0.166 0.310 0.425 0.575 0.022
75–79 0.191 0.310 0.442 0.558 0.035
80+ 0.215 0.460 0.576 0.424 0.057
a3% improve in overall 2-year AMI mortality in every two years were assumed for subsequent years
bc = a + (1-a)*b
cd = 1-c
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Table 4 Prevalence of myocardial infarction in NHANES participants (%)a
1999 2001 2003 2005 2007 2009 2011
Men
35–39 0.19 (0.31) 1.11 (0.74) 0.33 (0.43) 0 (0) 0.42 (0.4) 0.41 (0.4) 0.45 (0.44)
40–44 2.72 (1.13) 2.41 (0.99) 1.32 (0.79) 0.19 (0.3) 0.61 (0.52) 2.03 (0.88) 1.66 (0.86)
45–49 4.78 (1.72) 0.24 (0.33) 1.78 (0.98) 4.48 (1.45) 2.67 (1.07) 0.25 (0.31) 1.17 (0.75)
50–54 3.37 (1.42) 3.81 (1.31) 5.49 (1.73) 1.81 (0.96) 1.99 (0.84) 5.84 (1.43) 2.46 (1.02)
55–59 15.21 (3.26) 8.77 (2.37) 9.00 (2.63) 4.57 (1.82) 5.91 (1.72) 8.68 (1.86) 4.48 (1.46)
60–64 15.16 (2.43) 8.25 (1.97) 9.55 (2.13) 10.4 (2.23) 7.47 (1.54) 8.81 (1.76) 7.16 (1.58)
65–69 8.78 (2.06) 14.76 (2.8) 18.25 (2.86) 15.42 (2.85) 14.61 (2.52) 10.29 (2.06) 11.33 (2.30)
70–74 14.72 (2.72) 10.20 (2.29) 19.45 (2.93) 11.20 (2.58) 13.23 (2.52) 14.22 (2.55) 16.70 (3.10)
75–79 16.46 (3.24) 18.81 (3.51) 11.82 (2.7) 21.68 (3.89) 16.75 (2.88) 16.89 (3.16) 10.38 (2.87)
80+ 17.47 (2.78) 20.83 (2.67) 21.99 (2.8) 22.73 (3.06) 22.34 (2.98) 17.29 (2.67) 14.93 (2.77)
Women
35–39 0 (0) 0.36 (0.38) 0 (0) 0 (0) 0.79 (0.55) 0.47 (0.41) 0 (0)
40–44 0.08 (0.2) 0.73 (0.55) 0.41 (0.44) 1.89 (0.91) 0.78 (0.56) 1.74 (0.75) 1.53 (0.79)
45–49 0.63 (0.57) 0.14 (0.25) 2.79 (1.2) 0.88 (0.66) 1.80 (0.84) 1.87 (0.8) 0.54 (0.49)
50–54 1.36 (0.86) 2.01 (1.02) 3.19 (1.29) 3.52 (1.37) 2.35 (0.98) 1.9 (0.85) 0.90 (0.58)
55–59 1.18 (0.99) 2.90 (1.41) 4.57 (1.85) 1.93 (1.18) 1.89 (0.94) 1.54 (0.88) 4.34 (1.42)
60–64 3.79 (1.28) 5.97 (1.63) 4.57 (1.43) 4.24 (1.46) 3.93 (1.12) 3.16 (1.03) 2.70 (0.98)
65–69 6.28 (1.78) 4.39 (1.58) 6.50 (1.83) 5.87 (1.95) 3.94 (1.37) 1.79 (0.96) 5.73 (1.76)
70–74 4.71 (1.65) 8.31 (2.18) 8.15 (2.21) 6.78 (2.18) 8.16 (1.91) 2.51 (1.07) 11.13 (2.53)
75–79 7.65 (2.39) 13.50 (3.03) 11.38 (2.81) 7.53 (2.78) 5.39 (1.80) 1.84 (1.14) 4.55 (2.05)
80+ 9.92 (1.95) 11.44 (1.81) 12.63 (1.93) 11.29 (2.21) 12.45 (2.13) 8.54 (1.88) 11.20 (2.26)
aEstimated with proper weighting variables and survey design. Mean (SE) for all values
Table 5 Cohort mortality for Canadian population with and without heart disease in 2001a
















15–34 0.043 0.012 0.180 0.952 0.001
35–49 0.087 0.018 0.180 0.915 0.001
50–54 0.121 0.024 0.190 0.908 0.002
55–59 0.135 0.032 0.300 0.826 0.002
60–64 0.240 0.032 0.300 0.838 0.004
65-69 0.261 0.058 0.470 0.729 0.006
70–74 0.391 0.058 0.470 0.718 0.010
75–79 0.420 0.130 0.640 0.545 0.015
80+ 0.619 0.130 0.640 0.553 0.025
Women
15–34 0.086 0.014 0.220 0.957 0.001
35–49 0.174 0.120 0.174 0.924 0.001
50–54 0.180 0.020 0.110 0.858 0.001
55–59 0.199 0.028 0.320 0.829 0.002
60–64 0.275 0.028 0.320 0.775 0.003
65–69 0.293 0.050 0.430 0.756 0.004
70–74 0.425 0.050 0.430 0.743 0.006
75–79 0.442 0.108 0.560 0.649 0.010
80+ 0.576 0.108 0.560 0.636 0.016
ad = 1- (weighta*a + weightb*b + weightc*c). weighta = proportion of MI to all heart disease in CCHS 2001 wave; weightb = proportion of angina to all heart disease
in CCHS 2001 wave; weightc = proportion of heart failure to all heart disease in CCHS 2001 wave. CCHS: Canadian Community Health Survey
Hu et al. BMC Medical Research Methodology  (2017) 17:9 Page 8 of 12
Table 6 Prevalence of heart disease in CCHS participants (%)a
2001 2003 2005 2007 2009 2011
Men
15–19 0.47 (0.09) 0.59 (0.10) 0.62 (0.18) 0.52 (0.17) 0.52 (0.17) 0.18 (0.10)
20–24 0.58 (0.13) 0.90 (0.17) 0.55 (0.12) 0.83 (0.16) 0.83 (0.15) 1.00 (0.17)
25–29 0.57 (0.12) 0.52 (0.12) 0.48 (0.11) 0.55 (0.12) 0.55 (0.13) 0.66 (0.14)
30–34 0.75 (0.13) 0.71 (0.12) 0.79 (0.13) 0.42 (0.10) 0.42 (0.12) 0.58 (0.13)
35–39 1.12 (0.14) 1.14 (0.15) 1.03 (0.14) 0.80 (0.13) 0.80 (0.16) 0.98 (0.17)
40–44 1.90 (0.17) 2.02 (0.19) 1.89 (0.18) 1.76 (0.19) 1.76 (0.19) 1.26 (0.18)
45–49 3.23 (0.24) 3.48 (0.27) 3.19 (0.27) 2.79 (0.24) 2.79 (0.28) 3.24 (0.30)
50–54 6.23 (0.35) 5.87 (0.33) 5.55 (0.34) 5.74 (0.33) 5.74 (0.34) 5.27 (0.34)
55–59 10.59 (0.49) 9.49 (0.43) 9.91 (0.43) 8.80 (0.40) 8.80 (0.42) 9.19 (0.40)
60–64 12.99 (0.59) 14.10 (0.55) 12.50 (0.51) 12.34 (0.48) 12.34 (0.49) 12.94 (0.46)
65–69 18.36 (0.70) 17.78 (0.64) 17.51 (0.64) 17.87 (0.62) 17.87 (0.59) 16.02 (0.55)
70–74 22.54 (0.81) 21.84 (0.74) 22.27 (0.76) 21.31 (0.73) 21.31 (0.74) 20.45 (0.70)
75–79 27.47 (1.01) 26.53 (0.91) 25.96 (0.9) 24.22 (0.84) 24.22 (0.85) 22.78 (0.83)
80+ 27.69 (1.04) 28.71 (0.96) 28.93 (0.93) 28.78 (0.87) 28.78 (0.86) 29.01 (0.81)
Women
15–19 0.60 (0.10) 0.60 (0.10) 0.79 (0.20) 0.35 (0.14) 0.35 (0.20) 0.56 (0.19)
20–24 0.75 (0.14) 0.49 (0.12) 0.82 (0.14) 0.43 (0.11) 0.43 (0.10) 0.69 (0.14)
25–29 0.61 (0.11) 0.77 (0.13) 1.00 (0.14) 0.63 (0.12) 0.63 (0.12) 0.65 (0.12)
30–34 0.95 (0.13) 0.73 (0.12) 0.65 (0.11) 0.55 (0.10) 0.55 (0.13) 0.54 (0.11)
35–39 0.95 (0.12) 0.96 (0.13) 1.10 (0.15) 0.75 (0.12) 0.75 (0.12) 0.86 (0.14)
40–44 1.76 (0.16) 1.84 (0.19) 1.32 (0.15) 1.50 (0.17) 1.50 (0.16) 1.40 (0.18)
45–49 2.52 (0.21) 2.78 (0.22) 2.19 (0.21) 1.86 (0.19) 1.86 (0.24) 1.84 (0.22)
50–54 3.41 (0.25) 3.23 (0.23) 3.18 (0.23) 3.35 (0.23) 3.35 (0.26) 3.44 (0.25)
55–59 5.89 (0.36) 5.65 (0.30) 5.06 (0.29) 4.87 (0.27) 4.87 (0.27) 4.53 (0.26)
60–64 9.02 (0.46) 9.11 (0.42) 8.17 (0.39) 7.35 (0.34) 7.35 (0.33) 6.32 (0.30)
65–69 12.86 (0.55) 12.13 (0.49) 10.99 (0.48) 10.40 (0.45) 10.40 (0.42) 9.04 (0.38)
70–74 17.10 (0.62) 16.28 (0.56) 14.87 (0.56) 15.18 (0.56) 15.18 (0.54) 14.01 (0.53)
75–79 21.30 (0.72) 21.61 (0.67) 19.79 (0.67) 18.37 (0.63) 18.37 (0.62) 17.31 (0.62)
80+ 26.19 (0.70) 26.34 (0.65) 24.91 (0.63) 24.08 (0.60) 24.08 (0.61) 23.41 (0.58)
aEstimated with proper weighting variables and survey design. Mean (SE) for all values
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Table 7 Hospitalized MI incidence in different states in the U.S. from 2000 to 2012a
State 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
Arizona – – – – – 32.6 31.0 29.3 30.0 28.3 28.4 27.2 26.8
California 42.2 41.6 40.2 39.3 36.4 34.2 32.1 30.9 30.3 28.4 28.5 27.7 –
Colorado – – – – 30.5 28.4 27.8 25.5 24.6 23.5 22.0 21.3 21.0
Connecticut 46.5 43.1 42.4 41.8 38.9 35.3 31.7 31.6 33.5 30.6 29.2 26.6 29.1
Florida 50.2 49.2 47.9 46.6 43.7 41.3 38.0 36.4 35.5 33.0 32.8 30.6 30.9
Iowa 43.9 44.2 41.5 39.0 37.0 35.0 34.3 32.9 33.0 29.3 30.7 29.0 29.0
Kansas 42.3 39.6 38.3 38.2 36.3 34.0 33.1 30.3 30.2 28.2 26.5 26.6 26.3
Louisiana 37.1 38.9 40.9 37.5 37.2 30.2 29.9 30.1 31.3 32.3 31.7 33.3 –
Maine – 67.1 65.6 65.6 57.3 57.8 55.4 53.2 49.7 46.6 46.0 45.2 –
Maryland 49.5 49.1 47.1 46.2 39.7 36.9 33.5 30.9 30.1 29.3 – 27.6 –
Massachusetts 50.6 51.0 50.9 51.1 45.4 42.1 40.1 37.8 35.9 34.0 32.8 30.8 30.1
Minnesota 42.7 42.3 40.6 37.8 35.8 35.9 33.8 31.3 31.0 28.8 27.8 26.7 26.9
Missouri 53.5 53.8 54.3 52.0 46.7 44.6 42.2 39.6 39.2 38.1 36.5 35.2 –
New Hampshire 50.2 48.6 45.4 45.7 40.7 38.7 37.8 38.4 36.0 33.7 27.9 – –
New Jersey 50.1 48.8 49.2 46.7 42.9 39.9 37.9 36.3 37.0 35.4 35.2 33.7 33.6
New Mexico 35.7 35.0 32.9 31.8 30.5 27.3 31.7 30.0 28.9 27.1 26.2 – –
New York 47.5 47.0 46.5 45.6 42.9 39.0 36.0 32.7 32.7 30.7 30.4 29.1 29.3
North Carolina 54.3 52.5 51.6 50.3 46.4 45.2 43.1 39.9 40.5 38.7 37.3 – –
Oregon 35.0 34.7 35.7 34.5 31.5 30.2 29.9 29.6 28.8 26.7 24.9 24.6 24.7
Pennsylvania 56.5 54.4 53.4 52.0 48.1 44.8 42.7 40.1 39.7 37.4 35.8 35.1 35.0
South Carolina 50.5 49.4 47.8 45.7 41.5 40.5 39.1 37.4 36.4 33.4 32.9 32.6 31.8
Tennessee 53.1 52.1 53.6 51.1 45.8 45.5 45.2 43.1 42.4 41.1 42.4 41.4 –
Utah 36.6 33.7 33.8 30.7 27.6 24.8 25.1 22.1 22.5 21.1 21.1 22.6 21.4
Vermont – 54.4 49.7 45.8 40.9 43.6 40.8 40.0 40.3 34.6 25.1 – –
Washington 37.8 36.6 37.1 34.5 32.6 31.0 29.3 28.5 27.4 25.9 25.8 24.9 25.6
Wisconsin 43.6 43.5 41.8 39.1 37.4 35.6 33.5 32.2 31.7 29.0 29.4 28.7 28.7
aAge standardized MI hospitalization rate for people aged 35 years and older
–no data available
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